CSPC Pharmaceutical Group Limited (CSPCY)
OTCMKTS
· Delayed Price · Currency is USD
3.150
+0.030 (0.96%)
Apr 23, 2025, 4:00 PM EDT
CSPC Pharmaceutical Group Revenue
In the year 2024, CSPC Pharmaceutical Group had annual revenue of 29.01B CNY, down -7.76%. CSPC Pharmaceutical Group had revenue of 6.32B in the quarter ending December 31, 2024, a decrease of -16.64%.
Revenue
29.01B CNY
Revenue Growth
-7.76%
P/S Ratio
2.29
Revenue / Employee
1.36M CNY
Employees
21,400
Market Cap
9.08B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 29.01B | -2.44B | -7.76% |
Dec 31, 2023 | 31.45B | 513.21M | 1.66% |
Dec 31, 2022 | 30.94B | 3.07B | 11.02% |
Dec 31, 2021 | 27.87B | 2.92B | 11.73% |
Dec 31, 2020 | 24.94B | 2.84B | 12.84% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
CSPC Pharmaceutical Group News
- 6 months ago - CSPC Pharmaceutical Group Limited goes ex dividend tomorrow - Seeking Alpha
- 7 months ago - AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline - Benzinga
- 7 months ago - Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge - Benzinga
- 7 months ago - Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher - Benzinga
- 7 months ago - US Stocks Open Lower; Dow Tumbles Over 150 Points - Benzinga
- 7 months ago - AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline - Benzinga